Lyfegen collaborating with Johnson & Johnson
The Basel-based startup Lyfegen has developed a platform for value-based healthcare. This should provide improved outcomes for patients and result in cost-savings. Lyfegen teamed up with Johnson & Johnson for the implementation.
Girisha Fernando, Frederico Braga, Michel Mohler and Nico Mros from Lyfegen HealthTech AG (img: Lyfegen)
The concept of value-based healthcare is rooted in the definition of patient outcome per franc spent. By aligning all processes with this approach, the aim is to improve patient outcomes and reduce healthcare costs at the same time. Founded in 2018, the Basel-based company Lyfegen has developed a platform that can be used to implement value-based healthcare processes. Lyfegen teamed up with the life sciences company Johnson & Johnson Switzerland and a “leading” Swiss hospital for the implementation process, which has now been brought to a close, further details of which can be found in a press release.
The patented Lyfegen platform automates the collection and analysis of all patient-related data. In this way, the aim is to achieve transparency with regard to the contract content, expenses and healthcare outcomes. Lyfegen describes the platform as a “blueprint” from which global hospitals, health insurance companies and life sciences providers all stand to benefit. “Covid-19 has shown us the urgent need for a more sustainable healthcare system”, comments Girisha Fernando, CEO of Lyfegen, in the press release. “With the implementation of value-based healthcare agreements on the Lyfegen platform, we are extremely proud to help Johnson & Johnson and hospitals to accelerate the transition to value-based healthcare and improve patient health outcomes at reduced cost”.
For Lyfegen, the agreed partnership represents a key “milestone”, the press release explains further. The Basel-based startup recently opened up a new investment round.
Share this article
You may also be interested in
KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European marketRead More
A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...Read More